Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I/II, Open Label, Single Arm, Two Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti Tumor Activity of glofitamab in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-cell Non-Hodgkin Lymphoma
Study Type: Treatment
Phase: I/II
NCTID: NCT05533775
Principal Investigator:
Kevin Ginn
A Randomized Phase II Study of CHOEP vs CC-486- CHOEP vs duvelisib- CHOEP in previously Untreated CD30 Negative Peripheral T-cell Lymphomas
Study Type: Treatment
Phase: II
NCTID: NCT04803201
Principal Investigator:
Marc Hoffmann
A Randomized Phase III Trial of Continuous Versus Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma
Study Type: Treatment
Phase: III
NCTID: NCT05976763
Principal Investigator:
Marc Hoffmann
A Phase I Study Evaluating SC262, a Hypoimmune, Allogeneic CD22-directed CAR T Cell Therapy, in Relapsed and/or Refractory Non-Hodgkin?s Lymphoma VIVID
Study Type: Treatment
Phase: I
NCTID: NCT06285422
Principal Investigator:
Forat Lutfi
A Randomized Phase II study of Brentuximab Vedotin NSC 749710 and Crizotinib NSC 749005 in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma ALCL IND 117117
Study Type: Treatment
Phase: II
NCTID: NCT01979536
Principal Investigator:
A Randomized Phase II Study of CDX-1127 Varlilumab in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial BELINDA
A Phase I/II, Dose-Exploration and Dose-Expansion Study Evaluating the Safety and Efficacy of Multiplex Base-Edited, Allogenic Anti-CD7 Car-T Cells BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia T-ALL or T-Cell Lymphoblastic Lymphoma T-LL
Study Type: Treatment
Phase: I/II
NCTID: NCT05885464
Principal Investigator:
Forat Lutfi
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
Study Type: Treatment
Phase: I/II
NCTID: NCT03323151
Principal Investigator:
Marc Hoffmann